In adults with MI and LVEF >40% after invasive care, β-blocker therapy did not reduce a composite adverse outcome at a median 3.7 y

Orly Leiva; Islam Y. Elgendy

doi:10.7326/annals-25-04532-jc

December 1, 2025Annals of Internal Medicine

In adults with MI and LVEF >40% after invasive care, β-blocker therapy did not reduce a composite adverse outcome at a median 3.7 y

View at Publisher

Ask AI

Bookmark

Share

Key Points

No reduction in composite adverse outcomes after β-blocker therapy in adults with MI.
The median follow-up was 3.7 years following invasive care.
Analysis focused on adults with LVEF greater than 40% post myocardial infarction.
Implications suggest potential reevaluation of β-blocker therapy in clinical practice.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Observational analysis revealed β-blocker therapy did not reduce composite adverse outcomes in adults after MI, highlighting potential reevaluation of treatment guidelines.

Abstract

GIM/FP/GP: [Formula: see text] Cardiology: [Formula: see text].

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Leiva et al. (2025) studied this question.

synapsesocial.com/papers/6932311e8e51979591dce225 https://doi.org/10.7326/annals-25-04532-jc

View at Publisher

Ask AI

Bookmark

Share

In adults with MI and LVEF >40% after invasive care, β-blocker therapy did not reduce a composite adverse outcome at a median 3.7 y

Key Points

No abstract yet

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

In adults with MI and LVEF >40% after invasive care, β-blocker therapy did not reduce a composite adverse outcome at a median 3.7 y

Key Points

No abstract yet

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading